Bristol-Myers Squibb (BMY) Plunges 4.67% in Four Days

Bristol-Myers Squibb (BMY) shares fell 0.59% today, marking the fourth consecutive day of decline, with a total drop of 4.67% over the past four days. The stock price hit its lowest level since September 2024, experiencing an intraday decline of 2.17%.

Analysts' ratings and price targets for Bristol-Myers Squibb (BMY) have shown mixed sentiment. In the current month, BMY has received 9 Buy Ratings, 24 Hold Ratings, and 3 Sell Ratings. The average analyst price target for BMY over the past 3 months is $57.77. This mixed sentiment could influence investor perception and stock price movements.

Bristol-Myers Squibb (BMY) is expected to report earnings growth, with an upcoming earnings release noted on April 17, 2025. Anticipation of financial performance and actual earnings results can significantly impact stock price movements. Investors are closely watching these developments as they could provide insights into the company's future prospects and financial health.